Dormann D, Montermann E, Klimek L, Weber B, Ebner C, Valenta R, Kraft D, Reske-Kunz A B
Klinische Forschergruppe Allergie, Universitäts-Hautklinik, Mainz, Deutschland.
Int Arch Allergy Immunol. 1997 Nov;114(3):272-7. doi: 10.1159/000237679.
Immunodominant epitopes of Bet v 1a had been identified before, using recombinant (r) Bet v 1a-reactive T cell clones generated from peripheral blood mononuclear cells of patients allergic to birch pollen. This study aimed at evaluating the T cell-stimulating capacity of immunodominant Bet v 1a-derived peptides in a polyclonal system corresponding more closely to the situation in patients.
Short-term T cell lines (TCL) were established in presence of a protein extract of birch pollen (BP extract). TCL proliferation induced by the BP extract, by natural Bet v 1, rBet v 1a, rBet v 2 or 5 selected immunodominant Bet v 1a-derived peptides was determined.
Consistent with the knowledge that Bet v 1 is the major IgE-binding allergen of birch pollen, we found comparable T cell reactivity to natural Bet v 1 and the BP extract within the majority of the TCL. Accordingly, the response to rBet v 2 was low compared with the reactivity to the BP extract. The response of the TCL to rBet v 1a proved to be highly heterogeneous. Furthermore, the TCL response to the 5 immunodominant Bet v 1a-derived peptides showed considerable diversity. The proliferative responses of most TCL (with one exception) following stimulation by these peptides were low, in relation to the expansion induced by the BP extract.
These findings argue against the use of selected peptides derived from Bet v 1a in specific immunotherapy of patients with birch allergy.
此前已利用从桦树花粉过敏患者外周血单个核细胞中产生的重组（r）Bet v 1a反应性T细胞克隆，鉴定出Bet v 1a的免疫显性表位。本研究旨在评估免疫显性Bet v 1a衍生肽在更接近患者实际情况的多克隆系统中的T细胞刺激能力。
在桦树花粉蛋白提取物（BP提取物）存在的情况下建立短期T细胞系（TCL）。测定BP提取物、天然Bet v 1、rBet v 1a、rBet v 2或5种选定的免疫显性Bet v 1a衍生肽诱导的TCL增殖。
鉴于Bet v 1是桦树花粉主要的IgE结合变应原这一认识，我们发现大多数TCL中对天然Bet v 1和BP提取物的T细胞反应性相当。因此，与对BP提取物的反应性相比，对rBet v 2的反应较低。TCL对rBet v 1a的反应证明高度异质性。此外，TCL对5种免疫显性Bet v 1a衍生肽的反应显示出相当大的多样性。与BP提取物诱导的扩增相比，这些肽刺激后大多数TCL（有一个例外）的增殖反应较低。
这些发现不支持在桦树过敏患者的特异性免疫治疗中使用从Bet v 1a衍生的选定肽段
